Phase I, Non-Randomised, Open-Label, Multi-Centre Dose Escalation Trial of BI 764532 (DLL3/CD3 IgG-like T Cell Engager [tce]) Plus Ezabenlimab (Anti-Pd-1 Antibody) in Patients (pts) with Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Carcinomas (necs) Expressing DLL3
ANNALS OF ONCOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined